INmune Bio (NASDAQ:INMB) Given New $2.50 Price Target at Freedom Broker

INmune Bio (NASDAQ:INMB) had its price target lowered by analysts at Freedom Broker from $4.00 to $2.50 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Freedom Broker‘s price target points to a potential upside of 133.86% from the company’s previous close.

Several other research firms also recently commented on INMB. Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Wall Street Zen cut INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, INmune Bio currently has an average rating of “Moderate Buy” and an average price target of $2.50.

INmune Bio Trading Up 1.8%

NASDAQ INMB traded up $0.02 during trading on Friday, reaching $1.07. The company’s stock had a trading volume of 235,772 shares, compared to its average volume of 479,188. The stock has a market capitalization of $33.10 million, a PE ratio of -1.77 and a beta of 0.97. INmune Bio has a 1-year low of $1.01 and a 1-year high of $2.60. The business has a 50-day moving average price of $1.79 and a 200-day moving average price of $1.62.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02).

Institutional Trading of INmune Bio

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in INmune Bio in the 2nd quarter valued at $508,000. Russell Investments Group Ltd. lifted its position in INmune Bio by 64.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,246 shares of the company’s stock worth $49,000 after acquiring an additional 9,850 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in INmune Bio during the 2nd quarter worth $35,000. Ieq Capital LLC acquired a new position in INmune Bio during the 2nd quarter worth $134,000. Finally, GSA Capital Partners LLP bought a new stake in INmune Bio during the second quarter valued at about $134,000. 12.72% of the stock is owned by institutional investors.

About INmune Bio

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions. Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.